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ABSTRACT 
 
Cystic Fibrosis (CF) is an autosomal recessive disease caused 
by mutations in the cystic fibrosis transmembrane regulator 
(CFTR) gene, a member of the ATP-binding cassette (ABC) 
transporter superfamily. It acts in the apical part of epithelial cells 
as a plasma-membrane, cyclic AMP-activated chloride anion, 
bicarbonate anion and glutathione channel. CFTR is required for 
cell surface water-salt homeostasis and normal function of epithelia 
lining in the airways, intestinal tract, pancreatic ducts, salivary and 
sweat glands, liver and others. To date there are about 2000 
mutations reported in CFTR gene that are generally classified in 6 
different classes. The therapy of cystic fibrosis is still mainly 
simpthomatic but recently two novel classes of drugs were 
accepted for use in clinical practice even if in few patient with 
specific mutation called Ivafactor (potentiator of CFTR activity) 
and Lumafactor (corrector of CFTR activity). Although such  
therapies have improved the life expectancy of CFTR patients, they 
are still non resolutive in many cases and, moreover, are unable to 
work for all mutation’s classes. 
In order to identify novel molecules involved in CFTR 
transcriptional regulation, in addition to the correctors and 
potentiators that act at protein levels, we investigated the role of 
butyrate. Butyrate is a short-chain fatty acid and it is already in use 
in medical care. It’s involved in a variety of cellular events but is 
still unknown if it could have a putative role, direct or indirect, in 
the expression and modulation of CFTR. Preliminary data from our 
group indicate that butyrate enhance the CFTR expression in some 
cellular lines. To define if this effect is due to a direct mechanism 
on the CFTR promoter activity, we have focused our attention to 
the promoter region of CFTR gene to identify potential butyrate 
responsive elements (BRE) and their putative binding protein 
factors. To this purpose, we have performed a luciferase assay to 
compare the transcriptional activity of 6 deletion mutants of CFTR 
promoter. All constructs have showed a similar increase of 
luciferase activity under butyrate treatment in 3 different cell types: 
A549, Caco2 and Panc1. These data suggest that the butyrate effect 
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on CFTR promoter activity is not mediated by a specific BRE 
element but most probably it is related to the Histone Deacetylase 
(HDAC) inhibitor activity of butyrate, and we confirmed this 
mechanism by treatment with Tricostatin (TSA), a specific histone 
deacetylase inhibitor, that demonstrated the same effect of butyrate 
on CFTR expression. Our study confirms that butyrate enhance 
CFTR expression. Such effect is not due to the interaction of 
butyrate with promoter responsive elements, but it depends on its 
effect on histone deacetylase inhibitor activity. Butyrate might be 
useful in patient with CF bearing mutations that permit a residual 
activity of the protein enhancing CFTR expression.   
4 
 
 
INTRODUCTION 
 
 
1.1 Cystic Fibrosis 
 
Cystic fibrosis (CF) was described as a clinical syndrome, for 
the first time, in 1938 and identified as a disease by Dorothy 
Andersen 
(1-4)
. She described cystic fibrosis of the pancreas in 49 
patients and the disorder was subsequently associated with 
autosomal recessive inheritance pattern in 1949 
(1-4)
. It manifests 
with exocrine pancreatic insufficiency, intestinal obstruction 
(meconium ileus), liver disease, increased sweat Cl- concentrations, 
male infertility, and airway disease (Figure 1). In CF patients, 
airway disease tipically leads to progressive lung dysfunction, 
responsible for over 95% of CF related morbidity and mortality 
(Figure 2).  
CF is one of the most common mendelian life shortening 
disease in the world (Figure 3). The high incidence of CF carriers 
can be explained by a possible protective effect. Several works 
showed indeed that there is a heterozygote advantage for carriers of 
CFTR mutations. For example, Salmonella typhi, which is the 
etiologic agent of typhoid fever, was found to bind the CFTR 
protein. This binding mediates translocation of this pathogen into 
the gastrointestinal submucosa. Thus, decreased CFTR levels in the 
gastrointestinal epithelium of mice heterozygous for a CFTR 
mutation result in the resistance to typhoid fever  
(14)
. It was also 
shown that mice carrying a CFTR mutation have an increased 
resistance to cholera toxin 
(15)
. 
After the discovery of the abnormal Cl- transport in CF, the 
gene responsible for the disease was identified by Riordan, Tsui, 
Collins, and colleagues using linkage-based techniques and named 
cystic fibrosis transmembrane conductance regulator (CFTR) gene 
(7-8-9)
.  
CF is a classic Mendelian autosomal recessive disorder. It is 
most common in populations with northern European ancestry 
where the predominant mutation is Phe508del (also known as 
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F508del) 
(12,13)
. During the past six decades, median age of survival 
increased progressively, and now it is more than 40 years in 
developed countries 
(3,4)
. The number of adults with cystic fibrosis 
will continue to increase with almost all deaths occurring in the 
adult population 
(5)
. Indeed, in the past 5 years, in countries with 
well funded health-care systems, there were more adults than 
children with cystic fibrosis. In developed European countries, the 
number of adults with cystic fibrosis has been predicted to increase 
by around 70% by 2025 
(6)
. 
 
 
 
 
 
 
Figure 1. Health problems in patients with CF. 
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Figure 2. Representations of secretions disfunction in CF patients. 
 
 
 
 
 
 
Figure 3. World incidence of CF disease (WHO data) 
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1.2 CFTR structure and function 
 
The CFTR gene comprises 27 coding exons, spanning over 250 
kb on chromosome 7q31.2, and the transcript is 6.5 kb. It encodes a 
chloride (Cl
-
) channel in the apical membrane of exocrine epithelial 
cells 
(10) 
(Figure 4) that also acting as regulator of other 
transmembrane proteins. The CFTR protein, after its synthesis in 
the endoplasmic reticulum (ER), is glycosylated at Golgi level and 
transported to the apical plasma membrane 
(12)
. CFTR protein is 
expressed in the trachea, lung, pancreas and several tissues of the 
reproductive system 
(12,16,17)
.
 
It is regulated by ATP hydrolysis and 
phosphorylation, and conducts Cl-, HCO3 -, SCN-, and other 
anions. 
(18-22)
. The CFTR protein comprises 1,480 amino acids with 
a molecular weight of 170 kDa and five domains: two membrane-
spanning domains (MSD1 and MSD2), each composed of six 
transmembrane segments (TM1 to TM12) that form the channel, 
two nucleotide-binding domains (NBD1 and NBD2), with ATP 
hydrolytic activity, and a regulatory domain (R), which contains 
numerous phosphorylation sites 
(10,11)
 (Figure 5). The R-region 
contains several Protein Kinase A (PKA) phophorylation sites 
highly conserved 
(23,24)
. PKA is a cAMP-activated kinase, that 
phosphorylates CFTR when cellular levels of cAMP increase 
(23)
. 
According to many Authors, the R-region blocks the NBDs from 
associating together keeping the channel in a closed conformation. 
Phosphorylation causes a structural change that removes the R-
region from its steric-interfering position and allows NBD 
dimerization, triggering a much larger conformational change 
(23, 25-
27)
. Then, the binding of ATP initiate channel opening while 
channel closure is associated with ATP hydrolysis and release of 
ADP and inorganic phosphate 
(28,29)
. 
 
8 
 
 
 
Figure 4. Schematic diagram of the CFTR gene. a Structure of the CFTR gene 
consisting of promoter region (P) and 27 exons. b CFTR polypeptide with 
predicted domains (highlighted). c topology of the CFTR protein relative to the 
cytoplasmic membrane and position of the most common mutation, _F508. 
Box: Deletion of 3 nucleotides, CTT (underlined), and subsequent loss of 
phenylalanine 508 (underlined). 
 
 
 
 
 
Figure 5. CFTR schematic structure – Cystic fibrosis transmembrane 
conductance regulator (CFTR) is a 1,480-amino acids protein inserted into 
the cell surface. CFTR possesses five domains: two transmembrane domains 
(TMD1/2), containing six hydrophobic alpha-helices, which cross the cell 
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surface lipid bilayer, and are joined by two intracellular loops and three 
extracellular loops, and with glycosylated residues linked in the extracellular 
loop 4 (N894, N900); two nucleotide-binding domains (NBD1/2) with highly 
conserved sequenced for ATP-binding, where occur hydrolysis; and one 
regulatory domain (RD) with multiple phosphorylation sites. CFTR channel 
open when protein kinase A (PKA) and protein kinase C (PKC) 
phosphorylate RD and ATPs bind to side chain charged amino acids in 
NBDs, thereby activating CFTR function. TMDs form the gate where occurs 
chloride conductance. The positions denoted into the boxes correspond to the 
first and last amino acid of each fragment and CFTR sequence was obtained 
in the Cystic Fibrosis Mutation Database (CFTR Modulators: Shedding Light 
on Precision Medicine for Cystic Fibrosis. M. Lopes-Pacheco. Front 
Pharmacol 2016). 
 
In healthy subjects, CFTR is maintained in its correct apical 
plasma membrane location by the formation of a multiprotein 
complex made up of scaffold proteins (such as NHERF1) and 
signaling molecules (such as cAMP and protein kinases) 
guarantee its correct functioning 
(12)
.  
In CF, a disorganized and dysfunctional airway epithelium 
brings an altered flux of ions and water into the lumen of 
bronchioles, consequent bacterial infections and influx of 
inflammatory cells (mainly neutrophils) into the airway lumen 
(12)
. The lack/dysfunction of the CFTR protein causes the 
accumulation of sticky dehydrated mucus in various organs, 
such as lungs and pancreatic ducts. In the airways there is an 
abnormal ion and water flux consequent to decreased chloride 
secretion and hyperabsorption of sodium 
(30)
.  
 
1.3 CFTR gene mutations and classes 
 
The CFTR gene covers approximately 180,000 base pairs in 
the long arm of chromosome 7. The protein contains 1,480 
amino acids. Up to date, more than 2000 CFTR mutations have 
been reported in patients with classic CF and CFTR-RD 
(12, 28)
. 
Most mutations of the CFTR gene are missense alterations, but 
frameshifts, splicing, nonsense mutations, and inframe deletions 
and insertions have been described. 
(32)
. About 15% of identified 
genetic variants are not associated with disease 
(32)
. 
CFTR mutations are divided into six classes according to 
their effects on protein function (Figure 6).  
10 
 
Class I: Defective Protein Synthesis 
Class I includes mutations which lead to the disruption of 
the CFTR protein synthesis. The mutations in this class include 
nonsense and frameshifts, which lead to the creation of 
premature termination codons. Genotype-phenotype studies 
revealed that CFTR premature termination codon mutations are 
associated with a severe form of the disease 
(32)
. Common class I 
mutations are G542X (Britanny and Southern France), R1162X 
(Austria and Northern Italy), or W1282X  (reaching 48% 
amongst Ashkenazi Jews)  
(33)
  
Class II: Defective Protein Processing 
Class II mutations are associated with defective protein 
processing. Upon completion of the CFTR protein translation, 
the normal protein undergoes a series of processes in the 
endoplasmic reticulum (ER) and the Golgi apparatus. This 
includes glycosylation and folding that enable the protein 
trafficking to the apical cell membrane. Class II mutations cause 
impairment of this process, which leads to degradation of the 
abnormally processed protein. The major mutation, F508del, 
results in the synthesis of a CFTR protein that is unable to 
correctly fold into its appropriate tertiary conformation. 
Consequently, this protein is retained in the ER and abnormally 
degraded (99vs. 75% in normal proteins). 
(32)
 
Class III and IV: Defective Protein Regulation and Altered 
Conductance 
Phosphorylation and dephosphorylation of the CFTR is 
considered the major pathway by which the chloride channel 
activity is physiologically regulated. Class III includes 
mutations that lead to the production of proteins (e.g. G551D 
and Y569D), which reach the plasma membrane; however, their 
regulation is defective and, thus, they cannot be activated by 
ATP or cAMP. Class IV mutations are associated with altered 
conductance (e.g. R347P, R117H and D1152H) thus, the rate of 
chloride transport is reduced. Thus, mutations in both class III 
and IV lead to a CFTR protein that can be produced, processed, 
transported and inserted into the apical membrane, but with a 
defective conductance.  
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Class V: Reduced CFTR Level 
Class V mutations lead to the production of a normal 
protein, however at reduced levels. This class includes promoter 
mutations that reduce transcription and amino acid substitutions 
that cause inefficient protein maturation. Yet, most of the 
mutations are splicing mutations, which affect the normal 
splicing of the pre-mRNA and thus reduce the levels of correctly 
spliced mRNA, by partial exon skipping or inclusion of intronic 
sequences. These mutations account for 5% of CFTR mutations 
and can lead to variable levels of correctly spliced transcripts 
among different patients and among different organs of the same 
patient. 
(34,35)
 These levels were found to inversely correlate with 
the variable disease expression, such that lower levels of 
correctly spliced transcripts are associated with a severe disease, 
while higher levels are associated with milder disease. 
(36,37)
 
Class VI: Reduced CFTR stability 
Class VI mutations decrease retention/anchoring at the cell 
surface, often associated with decreased protein stability at the 
plasma membrane. 
(38)
 
 
Figure 6. Classes of CFTR mutations 
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can 
be divided into six classes. Class I mutations result in no protein production. Class II 
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mutations (including the most prevalent, Phe508del) cause retention of a misfolded 
protein at the endoplasmic reticulum, and subsequent degradation in the proteasome. 
Class III mutations affect channel regulation, impairing channel opening (eg, 
Gly551Asp). Class IV mutants show reduced conduction—ie, decreased flow of ions 
(eg, Arg117His). Class V mutations cause substantial reduction in mRNA or protein, or 
both, Class VI mutations cause substantial plasma membrane instability and include 
Phe508del when rescued by most correctors (rPhe508del).  
 
1.4 CF mutation based therapy 
 
The specific mutation, class and functional consequences 
are very important data to program treatments aimed to correct 
the basic molecular and cellular defects (i.e. mutation-specific 
therapies) 
(39)
. In class I, for example, aminoglycoside antibiotics 
(e.g. gentamicin), can over-read the premature termination 
codons permitting the normal termination of the transcript. For 
Class II, chemical and molecular chaperones can avoid part of 
protein degradation in ER by promoting protein folding: the 
consequence is an increase in the protein presence in the cell 
surface. These compounds have been called correctors (e.g. VX-
809, VX-661). In class III mutations, such as G551D, there is a 
class of molecules that have showed a therapeutic effect both in 
vitro and in clinical trials: these drugs, called potentiators (VX-
770, ivafactor) work as activators of CFTR channel. In the class 
IV mutations, there is a reduction in the conductance that can be 
compensated by increasing the overall cell surface amount of 
these CFTR mutants with correctors, alternatively increasing the 
levels of channel activation (by potentiators). In class V 
mutations, there is the reduction of normal protein levels, often 
by affecting splicing and generating both aberrant and normal 
transcripts. So recent advances in the use of antisense 
oligonucleotide (AONs) make this promising approach a very 
powerful tool for the specific correction of misplicing. 
Meanwhile also potentiators and correctors may have some role.  
Although the therapies have improved the life expectancy 
of CF patients, they are still non resolutive in many cases and, 
moreover, are unable to work for all mutation’s classes. 
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1.5 Transcriptional regulation of CFTR 
 
CFTR protein production is tightly regulated in the different 
tissues of human organism: it is mainly expressed in epithelial 
cells of respiratory and digestive systems, in the pancreatic duct 
epithelium and in the crypts of small intestine 
(40-43)
. Low CFTR 
expression are described in many other tissue such as heart, 
brain, muscle 
(44)
. 
The promoter of CFTR gene, like an housekeeping gene, is 
rich in CpG islands and has a lot of transcription start sites and 
multiple binding sites for putative transcription factors Sp1 and 
AP-1 
(45,46)
. Some authors showed that the inhibition of AP-1 
binding site decrease CFTR transcription 
(46)
.  
Promoters of constitutively expressed genes are often rich 
in CpG sites, generally not methylated, while tissue specific 
genes usually are poor in CpG sites, often not methylated 
(47)
. 
There is an inverse correlation between CFTR promoter 
methylation and gene expression in cell lines 
(48)
. 
The transcriptional regulation of CFTR also required a 
conserved sequence element CCAAT, named Y-box 
(49)
. This Y-
box element is crucial for the transcription regulation of CFTR 
gene mediated by transcription factor ATF-1 and human histone 
acetyl transferase protein GCN5 
(49, 50)
.  
Li et al. showed that levels of histone acetylation at the 
CFTR promoter are an indicator of CFTR transcription and that 
the effect of histone deacetylation by trichostatin A increases 
CFTR transcription 
(50)
.  
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1.6 Butyrate: mechanisms and effects 
 
Among short chain fatty acid (SCFAs), butyrate has 
received a particular attention for its multiple beneficial effects, 
from the intestinal tract to the peripheral tissues. The butyrate is 
a fatty acid with numerous and diverse effects on cellular 
physiology 
(51)
. It is a natural substance present in the 
gastrointestinal tract, in milk as well in the sweat and feaces of 
most mammals. Butyrate is naturally present in high 
concentration in the lumen of the large intestine: it is 
preferentially taken up by the colonic epithelium where is 
actively metabolized to produce energy 
(51)
.  
Butyrate has multiple mechanism of action: many of these 
are directly correlate to its gene expression regulatory effects. In 
particular, butyrate is one of some molecules that have an 
important epigenetic influence known as histone deacetylase 
inhibitors (HDACi) 
(51)
.  
Butyrate and phenylbutyrate are drugs already in use. One 
of their application is in neoplasia because for years have been 
shown to have HDACi activity. These SCFAs have HDACi 
activity at millimolar concentrations and have been described to 
have antiangiogenic and antimetastatic effects. Butyrate was 
found to repress angiogenesis, both in vitro and in vivo, and to 
reduce expression of proangiogenetic factors, including hypoxia 
inducible factors (HIF-1a) and vascular endothelial growth 
factor (VEGF) 
(53-55)
. Butyrate also inhibits nuclear factor B  
(NFkB) activation, reduces the production of interferon gamma 
and the upregulation of peroxisome proliferator-activated 
receptor g (PPARg) by its inhibition of HDAC 
(51)
. This confers 
to butyrate an anti-inflammatory effect that has been evaluated 
for its potential therapeutic capacity in the treatment of 
inflammatory bowel disease (IBD). Another important aspect of 
butyrate, actually under study, is its epigenetic regulation of the 
immune system, both innate and acquired. In particular, butyrate 
seems to play multiple anti-inflammatory activities by affecting 
immune cell migration, adhesion, cytokine expression and 
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modulating cellular processes such as proliferation, activation 
and apoptosis 
(56)
. Finally, butyrate is used in some genetic 
diseases such as thalassemia or Congenital Chloridorrea. In 
thalassemia, butyrate showed the capacity to induce the 
synthesis of fetal hameoglobin (HbF) that is a therapeutic 
strategy for the treatment of beta thalassemia.  Butyrate is also 
an inducer of SLC26A3 gene expression, whose mutations are 
involved in the pathogenesis of Congenital chloride diarrhea 
(51)
. 
In conclusion butyrate is useful in the prevention and treatment 
of different chronic disorders such cancer, inflammatory 
disorders, cardiovascular diseases and immune-mediated 
chronic disorders 
(51)
. 
 
1.7 Butyrate and CF 
 
Butyrate and its derivatives have been investigated as 
potential molecules for the treatment of cystic fibrosis but their 
role in the disease and on CFTR regulation is still unknown. 
There are several sporadic studies that describe various aspects 
and effects of butyrate on CFTR gene expression, function or 
both 
(51, 55, 58, 61-65)
. 
It is reported, for example, that butyrate can increase the 
protein trafficking pathway by manipulation of chaperone 
protein/CFTR interactions and then improve the CFTR activity 
in patient with class II mutations 
(51)
. Some studies, in fact, 
demonstrated an increased production of mature CFTR and 
chloride transport at the cell surface 
(51)
. The mechanism is still 
not fully understood but is probably due to an upregulation at 
the transcriptional level and modulation of protein folding step 
(51, 57)
. Some data suggest that 4-Phenylbutyrate (4PBA) may 
improve CFTR trafficking by allowing a greater proportion of 
mutant CFTR to escape association with Hsc70 chaperone 
protein 
(58)
. 
Singh et al, identified multiple putative butyrate-responsive 
cellular chaperones, protein processing enzymes and cell 
trafficking molecules associated with the amelioration of the 
chloride transport in cystic fibrosis bronchial epithelial cells 
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defect treating these cells with 4PBA and analyzing protein 
profiles by two-dimensional gel electrophoresis and mass 
spectrometry 
(59)
.  
Others authors suggested that butyrate and the butyrate 
analog 4-phenylbutyrate may be therapeutic agents for treatment 
of CF in patients that carring the F508del CFTR mutation 
(61-63)
. 
These molecules partially restored cAMP-activated Cl
-
 secretion 
in nasal, bronchial, and pancreatic epithelial cells expressing 
F508del CFTR by stimulating F508del CFTR gene expression 
and increasing the amount of F508del CFTR protein in the 
plasma membrane 
(61-63)
. It was also demonstrated that butyrate 
increases apical membrane CFTR but reduces chloride secretion 
in MDCK cells: this inhibition of cAMP-stimulated Cl
-
 secretion 
across MDCK cells is in part caused by the reduction of the 
activity of the Na-KATPase 
(60)
.  
One study quantifies the double effect of sodium butyrate 
and low temperature on CFTR protein expression at the cell 
surface of F508del cells demonstrating that these two 
interventions are synergistic regarding their ability to upregulate 
the expression of F508del CFTR 
(64)
. 
Nguyen et al. showed that some short chain fatty acids can 
restore chloride secretion in cystic fibrosis 
(65)
. In particular, they 
demonstrated that 2,2-dimethyl-butyrate and alpha-
methylhydrocinnamic acid, exhibiting high oral bioavailability 
and sustained plasma levels, can correct the F508del CFTR 
trafficking defect 
(65)
. 
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2. AIM 
 
In order to identify novel molecules involved in CFTR 
transcriptional regulation, we investigated a putative role of 
butyrate in the modulation of CFTR expression. 
Butyrate is a short-chain fatty acid and it is already in use in 
medical care. It’s reported to function as a modulator of CFTR 
and is involved in a variety of cellular events.  
The aim of our project is to investigate the butyrate effects 
on CFTR expression by studying its molecular mechanism and 
in particular: 
 
• evaluating the butyrate effect on promoter activity of 
CFTR gene in different cell lines 
 
• looking for putative butyrate responsive element (BRE) in 
the promoter of CFTR 
 
• defining its effect on deacethylation of CFTR 
 
Given the role of butyrate in the regulation of CFTR gene 
expression, it is a candidate molecule to be used: 
i) to enhance CFTR expression in patients with CF that bear 
mutation that permit some residual activity of the protein at 
membrane level 
ii) in association with correctors and potentiators of CFTR 
protein 
 
  
18 
 
 
3. MATERIALS AND METHODS 
  
3.1 Cell Culture 
 
Cell lines were purchased from ATCC (Manassas, VA) and 
Lonza, SW. Human diploid fibroblast strain (IMR-90, ATCC 
number CCL-186), were grown in Eagle's Minimum Essential 
Medium (Gibco Invitrogen, Grand Island, NY). Normal human 
renal proximal tubule epithelial cells (RPTEC, Lonza, SW), 
were maintained in Renal epithelial cell basal medium (REBM 
Clonetics, USA), Human Bronchial Epithelial Cells (NHBE, 
Lonza, SW), in Bronchial Epithelial Cell Growth Medium 
(BEGM Clonetics, USA). Human colon primary cells were 
purchased by Celprogen, (CA) and seeding according to the 
manufacturer’s. Cells were placed in CELL+T 25 flasks 
(Sarsdet) and maintained in culture with human colon cell 
culture complete growth serum free medium. Initial seeding 
density was 3000 viable cells/mm3 per flask.Medium was 
changed daily.  
A549, Panc-1 and Caco2 cells were maintained in 
Dulbecco’s modified Eagle’s medium (Gibco Invitrogen) with 
10% heat inactivated fetal bovine serum (HyClone), 2.5 mmol/L 
L-glutamine and 100 unit/ml Pen-Strep (Invitrogen). Cells were 
placed in Corning 100 x 20 mm Style Tissue Culture Dish in 5% 
(v/v) CO2 humidified atmosphere at 37°C. The medium was 
changed daily.   
 
3.2 Real-Time PCR of CFTR 
 
CFTR mRNA extraction and quantification 
Total RNA is isolated from cells using TRIzol reagent 
(Invitrogen, Italy) according to the manufacturer protocol. RNA 
concentration and purity is determined with a NanoDrop ND- 
1000 spectrophotometer; reverse transcription is carried out on 1 
μg of total RNA resuspended in DEPC-treated nano pure water 
using QuantiTect Rev Transcription Kit (Qiagen) using the 
protocol supplied by the manufacturer. To check levels of CFTR 
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transcripts in the cells, relative quantification by real-time PCR 
is performed in duplicates using LightCycler 480 Probes Master 
containing CFTR primers (Roche, Italy) and a TaqMan CFTR 
probe (ID. Assay 102716). Amplification is carried out with the 
LightCycler 480 Systems for Real-Time PCR (Roche) with a 
two-step PCR protocol (preincubation of 10 min at +95° C 
followed by 45 cycles of amplification: 95°C for 10 sec, 60°C 
for 25s, 72°C for 1s). mRNA quantification results are 
normalized using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) gene (Roche, ID. Assay 101128) as an endogenous 
control. 
 
3.3 Treatment of cells with butyrate 
 
Human primary cells were plated at a density of 4000 
cells/cm
2
 in CELL + T 25 flasks (Sarstedt Ltd, UK). The 
butyrate was added in fresh medium for 24 hours at sixth day, at 
different concentration. Cells were harvested for extraction of 
RNA and DNA. Control cells were incubated without the 
addition of butyrate. 
 
3.4 Transfection and Luciferase Assay 
 
Transfection of A549, CaCo2, Calu3 and Panc-1 cells with 
the 6 constructs (3kb, 2kb, 1kb, 0,5kb, 0,3kb and 0,1kb  CFTR 
promoter cloned respectively into 6 different pGL3-basic 
luciferase vector) was performed with Attractene Transfection 
Reagent (Qiagen). Cells were seeded in 24-well plates and 24 hr 
after seeding the butyrate was added in fresh medium for 24 
hours in half of transfected cells. 
Twenty-four hours after treatment, cells were lysed and 
Renilla luciferase activities were determined using the Dual-Glo 
Luciferase Assay System (Promega Corporation). The relative 
reporter activity was obtained by normalization to the Renilla 
luciferase activity. Each experiment was done in triplicate and 
three independent experiments were performed for each 
construct tested.  
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3.5 Statistical Analysis 
 
Comparisons of promoter activity between WT and variant 
CFTR promoter constructs from luciferase assays were 
conducted by using the unpaired t-test; data were considered 
statistically significant at P < 0.001; data are expressed as means 
± StDv of three different assays. 
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4. RESULTS 
 
 
4.1 Effect of butyrate on CFTR mRNA level 
 
We tested the effect of butyrate on CFTR mRNA expression 
in different primary cells and in cell lines. In particular, all cells 
were exposed to standard or butyrate-containing medium, at 
different concentration, and the RNA was purified for Real-
Time PCR to compare the levels of CFTR mRNA. As shown in 
Figure 7, CFTR mRNA expression in all cell types, except on 
Calu3 cell line, was significantly increased by butyrate 
treatment. 
 
Figure 7. Effect of butyrate on the endogenous CFTR expression in human 
primary and cell lines. All cells were cultured in standard medium or 
butyrate-containing medium (5 mM, 24 h).  
 
4.2 Promoter-reporter construct preparation 
 
The human CFTR gene promoter constructs (pGL3b/CF-
2910, pGL3b/CF-1899, pGL3b/CF-916, pGL3b/CF-410, 
pGL3b/CF-224, and pGL3b/CF-58) were made by PCR method 
using the primer pairs shown in table 1. Each promoter fragment 
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was amplified by PCR from human genomic DNA using 
primers with adapters containing Kpn I restriction enzyme sites 
in the forward primer and Xho I in the reverse primer.  
 
 
 
 
 
 
 
 
Table 1. All primer used to amplify the CFTR promoter fragments. In red 
bold is shown the KpnI site and in blue bold the XhoI site. 
 
Each PCR fragment was directionally cloned into the 
pGL3-basic vector and confirmed by sequencing Figure 8.  
 
 
Figure 8. The figure is shown the six constructs with different fragments of 
CFTR promoter. 
 
4.3 Effect of butyrate on human CFTR gene promoter activity. 
 
To explore whether butyrate-mediated CFTR expression is 
due to increased gene transcription, we transfected different cell 
lines with our human CFTR gene promoter constructs followed 
by 24 h of treatment with 5 mM butyrate before analyzing 
promoter activity. In particular, we chose to test our constructs 
on Panc 1 and Calu3 cells. This is because CFTR expression, 
analyzed by qPCR assay, highlighted a different behavior in the 
two cell lines. In fact, the expression of CFTR increased in 
CFPR150-Luc5` GCAAATGGTACCAAGGCGGGGGAAAGA 
CFPR300-Luc5` GCAAATGGTACCTGGGAGTCAGAATC 
CFPR500-Luc5` GCAAATGGTACCCTGACGCGAAGGAG 
CFPR1000-Luc5` GCAAATGGTACCTGACTGAGACTAGG 
CFPR2000-Luc5` GCAAATGGTACCTGTTTCACTCTTTCC 
CFPR3000-Luc5` GCAAATGGTACCACAGATTGTTTAGG 
CFPRO-Luc3` GATATTCTCGAGCAAGCTCCTAATGCC 
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Panc1 and greatly decreased in Calu3 cell line after treatment 
with sodium butyrate.  
Unfortunately, although we had used several transfectants, 
from cationic liposomal formulation to electroporation methods, 
the Calu3 cell transfection efficiency did not have a good 
luciferase signal in contrast to Panc1 cells Figure 9. 
Surprisingly, no significant differences were observed between 
the different constructs. 
 
 
Figure 9. Effect of butyrate on human CFTR gene promoter activity. Cells 
were cotransfected with pRL-CMV and pGL3 basic (pGL3b) or human 
CFTR promoter constructs (pGL3b/CF-2910, pGL3b/CF-1899, pGL3b/CF-
916, pGL3b/CF-410, pGL3b/CF-224, and pGL3b/CF-58). Butyrate was 
applied 24 h before measuring promoter activities and the degree of 
stimulation on CFTR promoter activity was considered as the ratio of relative 
activity in butyrate treated cells over relative activity in control cells. Results 
are means ± StDv from at least 3 different experiments.  
 
4.4 Use of lentiviral particles for cell transduction. 
 
In order to improve the Calu3 cell transfection efficiency, 
we decided to clone the expression cassette of the construct 
pGL3b/CF-2910, containing about 3kb of the CFTR promoter 
region and the luciferase coding region, in a lentiviral vector. To 
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transduce both Panc1 and Calu3 cells we used the supernatant of 
lentiviral, particles-producing 293T cells achieving good 
infection efficacy both in Panc1 and Calu3 cells. 
As the use of lentiviral infections leads to the integration of 
the viral genome into the cell one, we used these cells, Panc1-
CFTR-Luc and Calu3-CFTR-Luc, stably expressing the 
luciferase gene under the control of the CFTR promoter for our 
experiments with butyrate treatment. So, we treated Panc1-
CFTR-Luc and Calu3-CFTR-Luc cells with butyrate for 24 
hours before analyzing the luciferase activity. In Figure 10 is 
shown the luciferase activity from both cells after treatment with 
NaB in a dose dependent manner. The luciferase activity 
confirmed the endogenous CFTR expression in both cell lines. 
 
 
 
Figure 10. Luciferase activity in Panc1-CFTR-Luc and Calu3-CFTR-Luc 
cell lines. Contrary to Panc1 cells, 5 mM NaB treatment was able to suppress 
CFTR promoter activity in Calu3 cells by about 30%. Results are means ± 
StDv from at least 3 different experiments. 
 
Phase contrast microscopic observations showed a dramatic 
decrease in the nucleus-cytoplasmic ratio in Panc1, wich seems 
to acquire a senescent-like morphology. Conversely, the N/C 
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ratio seems to increase to a lesser extent in Calu3 cells, which 
instead increase in Figure 11, suggesting a butyrate-mediated 
growth arrest of Panc1. 
 
 
 
Figure 11. Treatment with 5 mM of sodium butyrate for 24 hr causes a large 
morphological and numerical change in Calu3 and Panc1 cells.  
 
Indeed, several studies have reported the effect of butyrate 
in inhibiting cell growth 
(63)
. So, we decided to analyze the 
expression of some genes involved in the cell cycle or in the 
process of senescence, a permanent condition of cell growth 
arrest, after 24 hr of butyrate treatment. Precisely, we have 
analyzed by qPCR the expression of cyclin A (CyclA), forkhead 
box-M1 (FOXM1), thymidylate synthase (TYMS), cyclin-
selective ubiquitin carrier protein (UBE2C) and p21WAF1(p21) 
genes as marker of cell cycle arrest and interleukin-6 (IL-6) and 
β-galactosidase (GLB1) as marker of inflammation and 
senescence. In Figure 12 is shown the results of the qPCR 
analysis. After 24 hr of butyrate treatment we found a down-
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regulation of Cycl A, FOXM1, UBE2C, and the up-regulation of 
p21 in Panc1 cell line according to a cell cycle arrest process. 
Conversely, in Calu3 cell line, we observed a  
 
 
 
Figure 12. qPCR analysis of some cell cycle genes Effect of 24hr treatment 
with 5 mM sodium butyrate on endogenous CFTR expression in Panc1 and 
Calu3 cell lines.  
 
down-regulation of CyclA, FOXM1, UBE2C, but not an up-
regulation of p21 gene. Moreover, analyzing the IL-6 and GLB1 
mRNA levels, we found both genes up-regulated in Panc1 cells 
and down-regulated in Calu3 cells 
 
4.5 Effect of butyrate on human CFTR gene promoter activity 
in A549 and Caco2 cell lines. 
 
To explore whether butyrate effect on CFTR gene promoter 
activity is cell line dependent, we transfected A549 and Caco2 
cell lines with our human CFTR gene promoter constructs 
followed by 24 h of treatment with 5 mM butyrate before 
analyzing promoter activity.  
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Figure 13. Effect of butyrate on human CFTR gene promoter activity in 
A549 and Caco2 cell lines. Cells were cotransfected with pRL-CMV and 
pGL3 basic (pGL3b) or human CFTR promoter constructs (pGL3b/CF-2910, 
pGL3b/CF-1899, pGL3b/CF-916, pGL3b/CF-410, pGL3b/CF-224, and 
pGL3b/CF-58). Butyrate was applied 24 h before measuring promoter 
activities and the degree of stimulation on CFTR promoter activity was 
considered as the ratio of relative activity in butyrate treated cells over 
relative activity in control cells. Results are means ± StDv from at least 3 
different experiments.  
 
As shown in Figure 13, all reporter gene expression driven by 
human CFTR promoter were significantly induced in butyrate 
treated A549 and Caco2 cells. There was an induction of 2-8 fold 
in the promoter activity, without significant difference between the 
various constructs with different deletion mutants. This suggest that 
probably the effect of butyrate is due to its histone hyperacetylation 
action. So, to test this hypothesis, we treated the Caco2 cells, 
transfected with all set of constructs, with 1 M trichostatin A 
(TSA) for 24 hr before the luciferase assay. 
 
 
 
Figure 14. CFTR promoter activity in Caco2 cells after treatment with 1 M of 
TSA or 5 mM of NaB for 24 hr before the luciferase assay.  
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As shown in Figure 14, each promoter activity was 
increased in a similar manner independently when treated with 
TSA or NaB, confirming the hypothesis that the effect of 
butyrate on CFTR promoter activity is due to its histone 
hyperacetylation action. 
 
 
 
30 
 
5. DISCUSSION 
 
Cystic Fibrosis is one of the most important mendelian life 
shortening disease in the world and it is due to mutations in 
CFTR gene. Up to date, more than 2000 CFTR mutations have 
been reported and divided into six classes, according to their 
effects on protein function 
(12,31)
. The specific mutation, class 
and functional consequences are very important informations 
because mutation based therapies become available in the last 
year. In particular, drugs known as potentiators and correctors 
are mainly used for the treatment of CF in patients with class II 
or III mutations 
(39)
. Although the therapies have improved the 
life expectancy of CFTR patients, they are still not resolutive in 
many cases.  
The aim of our work was to define the role of butyrate as a 
putative new drug for the therapy of CF by studying expression 
of CFTR gene. The expression of the CFTR gene is strictly 
tissue and cell specific. Of course, this tightly regulated 
expression is largely due to the promoter's activity 
(44)
. The 
promoter of CFTR gene is rich in CpG island and has a lot of 
transcription start sites and multiple putative transcription factor 
protein binding sites 
(45,46)
. Among these, we focused our 
attention on those that can be regulated by butyrate. 
The butyrate is a fatty acid with numerous and diverse 
cellular effects with multiple mechanism of action: many of 
these are directly correlated to its important epigenetic function 
of histone deacetylase inhibitors (HDACi) 
(51)
. Butyrate is 
reported to function as a potential useful molecule for the 
treatment of different diseases and it is already used in medicine. 
Several studies report that it has antiangiogenic, anti-metastatic, 
anti-inflammatory and immune-stimulations effects. Due to 
these capabilities butyrate finds application in treatment of some 
oncologic and autoinflammatory diseases 
(51,53,56)
. Butyrate has 
also been proposed as a potential therapeutic drug in the therapy 
of some genetic disease such as Thalassemia or Congenital 
Chloridorrea and Cystic Fibrosis, because it had multiple effects 
both at genetic and epigenetic levels 
(51)
. 
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However, to date there are no studies showing whether 
butyrate has a direct or indirect action on the transcription 
promoter activity of the CFTR gene. Our project had 
investigated the butyrate effects on CFTR expression by 
studying its molecular mechanism.  
We firstly showed that 24h of butyrate treatment causes a 
significant increase of CFTR in RPTEC, Colon and NHBe 
primary cell line and in Panc-1, A549 and Caco2 immortalized 
cells, while the CFTR mRNA level decrease in Calu3 cell line. 
In particular CFTR mRNA expression was increased by 2 or 4 
fold up after butyrate treatment, except for Colon and Calu3 
cells where the mRNA levels rise up than 20 fold and decrease 
down 8 fold respectively.  
Once the butyrate-dependent activation of CFTR gene 
promoter was confirmed in primary and transformed cells, we 
constructed a series of CFTR promoter deletion mutants to try to 
locate butyrate responsive elements into promoter regions. The 
six constructs (pGL3b/CF-2910, pGL3b/CF-1899, pGL3b/CF-
916, pGL3b/CF-410, pGL3b/CF-224, and pGL3b/CF-58) were 
transfected A549, Caco2 and Panc-1 cell lines, while lentiviral 
infection was used for Calu3 cells that resulted very difficult to 
transfect with. As expected, butyrate treatment increased CFTR 
promoter activity by up 2-4 fold in Panc1 and A549 and up 8 
fold in Caco2 cells. However, smaller constructs (pGL3b/CF-
224, and pGL3b/CF-58) have responded to butyrate treatment to 
a lesser extent as compared to the larger ones in Caco2 cells.  
These experiments suggest that the effect of butyrate is due 
to its histone hyperacetylation activity rather than the presence 
of a specific butyrate responsive element in CFTR promoter 
region. 
In fact, repeating the same experiment in Caco2 cells, 
treated this time with Trichostatin A, (TSA), a specific histone 
hyperacetylating agent, we note that the effect on the CFTR 
promoter is very similar to that of butyrate, confirming that the 
increase of the activity of the CFTR promoter is mainly due to 
histone hyperacetylation. 
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Concerning, the Calu3 cell line, the longer fragment of 
CFTR promoter (pGL3b/CF-2910) cloned into a lentiviral 
construct was down regulated by the butyrate treatment. 
Moreover, the observation of a dramatic decrease in the nucleus-
cytoplasmic ratio in Panc1, similar to a senescent-like 
morphology (changes that were not observed in Calu3 cells) 
prompted us to analyze some genes involved in cell cycle arrest 
process. Indeed, several studies have reported the effect of 
butyrate in inhibiting cell growth 
(66)
. The cell cycle is a set of 
events underlying cell proliferation. This complex machinery is 
characterized by cell cycle checkpoints that occur at the G1/S 
boundary, in S-phase, and during the G2/M-phases to monitor 
the fidelity with which genetic information is passed to future 
generations 
(70)
. So, we decided to analyze the expression of 
cyclin A (CyclA), forkhead box-M1 (FOXM1), thymidylate 
synthase (TYMS), cyclin-selective ubiquitin carrier protein 
(UBE2C) and p21WAF1(p21) genes as marker of cell cycle 
arrest and interleukin-6 (IL-6) and β-galactosidase (GLB1) as 
marker of inflammation and senescence. Cyclin A can activate 
two different cyclin-dependent kinases (CDK1 and CDK2) and 
functions both in S phase and in mitosis. Its up-regulation could 
contribute to tumorigenesis (cell cycle proliferation) and its 
down-regulation is a symptom of cell cycle arrest (i.e. cellular 
senescence) 
(68)
. FOXM1 (Forkhead box M1) is a proliferation-
associated transcription factor, which regulates the expression of 
cell cycle genes essential for DNA replication and mitosis 
(69)
. 
Thymidylate synthase (TYMS) is required for DNA replication 
and it plays an important role in the biosynthesis of the DNA-
component thymidylate (dTTP). Its deregulation is an essential 
feature of cell cycle progression or arrest
 (70)
. Cyclin-selective 
ubiquitin carrier protein (UBE2C) is involved in cell cycle 
progression because of its role in cyclin B destruction that is 
essential for exit from mitosis. Furthermore, UBE2C plays a key 
role in mitotic spindle checkpoint control 
(71)
. The p21 
(WAF1/CIP1) is a cell-cycle inhibitor directly controlled by p53 
and/or p53-independent pathways. It is involved in maintaining 
the G1cell-cycle arrest when the checkpoint is triggered by 
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different stimuli such as by DNA damage, in a p53-dependent 
fashion or during cellular differentiation, by p53-independent 
pathways 
(72, 73)
. After 24 hr of butyrate treatment we found a 
down-regulation of Cycl A, FOXM1, UBE2C, and the up-
regulation of p21 in Panc1 cell line according to a cell cycle 
arrest process. Conversely, in Calu3 cell line, we observed a 
down-regulation of CyclA, FOXM1, UBE2C, but not an up-
regulation of p21 gene. Moreover, analyzing the IL-6 and GLB1 
mRNA levels, we found both genes up-regulated in Panc1 cells 
and down-regulated in Calu3 cells. Although partial, analysis of 
some cell cycle genes seems to indicate that 24 hr treatment with 
5 mM of sodium butyrate causes cell cycle arrest in Panc1, and 
probably in other cell types analyzed where there is an increase 
in CFTR expression, and a partial proliferative effect, or no 
effect, in Calu3 cells. 
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6. CONCLUSION 
 
 
In conclusion, we showed that the increased butyrate-
dependent CFTR expression described in literature and 
confirmed by our study is mainly due to the histone 
hyperacetylating activity of butyrate and not as occurs for 
SLC26A3 gene, for the presence of butyrate responsive element 
in the CFTR promoter. Thus, these data suggest that butyrate, or 
butyrate derivatives, may be used as agents to increase 
expression of CFTR under certain clinical conditions. 
Of course, this work represents the beginning of 
understanding a specific aspect of the transcriptional regulation 
of the CFTR gene that needs to be thoroughly investigated.  
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